CCS Breakthrough Grant awarded for The Canadian Network for Psychedelic-Assisted Cancer Therapy
Published:Category: News
A new national initiative as been funded by the Canadian Cancer Society, through their Breakthrough Team Grant competition. The Canadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT), is bringing together researchers, clinicians, policymakers, and people living with advanced cancer to explore the potential of psychedelic-assisted therapy as a transformative approach to cancer care.
Read MorePublication: LYC1, REC4, CE8
Published:Category: Publications
Primary publications for LYC1: Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL, and REC4: Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy and CE8: Marizomib for patients with newly diagnosed glioblastoma. Read More
Publications: secondary analysis for MA5, PA6, CE6, CLC2, CRC6, CO17
Published:Category: Publications
A series of publication in relation to CCTG trials comprising secondary analysis, updated analysis and nested cohort. Read More
Trial closure: PA7
Published:Category: Trials
PA7: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma trial has permanently closed.
Primary Publication
The CCTG Annual Spring Meeting of Participants is fast approaching!
Published:Category: Group updates
The CCTG Annual Spring Meeting of Participants is fast approaching! We are excited to share important updates and additional information.
Read MoreCRA Lunch and Learn training program
Published:Category: Group updates
CCTG will be holding the next CRA Lunch and Learn on Wednesday March 26th, 2025, at 12 pm ET. Session 4 will cover the topic of Introduction to RIPPLE: CCTG's rostering and participants list system
CCTG is looking for a new gastro-intestinal patient representative
Published:Category: Group updates
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Gastro-Intestinal Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gastro-Intestinal Disease Site Committee, the Gastro-Intestinal Disease Site Executive Committee, and the CCTG Patient Representative Committee.
Read MorePublication: PR17 and MA5
Published:Category: Publications
PR17 trial publication: Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance
Patients who inherited the adrenal-permissive HSD3B1 allele had more favorable 5-year clinical progression-free survival and OS when treated with ADT plus enzalutamide or ADT plus nonsteroidal antiandrogen compared with their counterparts who did not have adrenal-permissive HSD3B1 inheritance.
Read More